PresentationsNX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology By AldenMC Production / April 2, 2024
PresentationsFindings From the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / March 21, 2024
PresentationsNX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology By AldenMC Production / March 20, 2024
PresentationsA First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / February 29, 2024
PresentationsInitial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / February 29, 2024
PresentationsRole of Ternary Complex Formation and Ubiquitylation Assays in Early Protein Degrader Discovery By AldenMC Production / December 15, 2023
PresentationsInitial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / December 11, 2023
PresentationsA First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / December 11, 2023
PresentationsA First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including Diffuse Large B-Cell Lymphoma By AldenMC Production / December 11, 2023
